

# Austrian Mortality Cohort Study 2023

Martin Busch & Tanja Schwarz

11<sup>th</sup> October 2023

EMCDDA DRD hybrid meeting 2023

Addiction Competence Centre of the Austrian National  
Public Health Institute REITOX Focal Point Austria

Gesundheit Österreich  
GmbH 

# Preconditions and preparatory efforts

- **Everyone** undergoing opioid agonist treatment (OAT) in Austria must be **notified by the medical officer supervising OAT** to the OAT-registry.
- The notification is possible by **unique identification** of the patient in the **population registry** only
- In Austria there is a system of **bPKs which are unique identifiers** for persons in different areas e.g., bPK health, bPK statistics ...
- The OAT-data are **pseudonymised** (encryption of the bPK-health) and stored in the **OAT-Statistic Register**
  - Personal data on sex and year of birth only
  - Treatment-related data on e.g., medication prescribed, start/end of treatment period, attending physician, ...
- Data on OAT in Austria are available in this form for the years **1987 to 2022**
- The Austrian General Mortality Register (GMR) includes full personal information of **all death cases and underlying cause of death**
- 2016 Change of the Austrian Narcotic Substances Act (SMG) in 2016 created the **legal framework** to link the OAT-Statistic Register with the GMR

# Austrian mortality cohort studies

## 2017

- Patients who started OAT from 1. 1. 2002 to 31. 12. 2016
- 24,892 OAT-patients followed 197,739 person years
- 1,526 death cases
  - Busch, Martin; Anzenberger, Judith; Uhl, Alfred (2019): Mortalität von Menschen mit Opioidabhängigkeit. Suchtmedizin, 21 (6). <https://www.ecomed-suchtmedizin.de/archiv/suchtmedizin-band-21-nr-6-2019>
  - Busch, Martin; Anzenberger, Judith (2019): Mortality during and after opioid substitution treatment in Austria 2002 to 2016. Lisbon Addictions 2019, 23. Oktober 2019, Lissabon. <https://jasmin.goeg.at/id/eprint/1058>

## 2023 – Work in progress

- Patients who started OAT from 1. 1. 2002 to 31. 12. 2021
- 35,030 OAT-patients
- 3,511 death cases



# Questions of interest

- Crude mortality rate, standard mortality ratio, cause-specific mortality
- Critical periods (risk episodes) of mortality e.g., risk at onset and cessation of OAT
- Risk episodes will be compared by age group, sex and OAT medication (if sample sizes in the subgroups are large enough), namely
  - Slow-release oral morphine (SROM)
  - Buprenorphine
  - Buprenorphine/naloxone
  - Methadone and levomethadone
- Change of (cause-specific) mortality over time

# Many thanks for your attention!

**Dr. Martin Busch**

Head of Department

Addiction Competence Centre of the Austrian National Public Health Institute

REITOX Focal Point Austria

**Gesundheit Österreich GmbH**

Stubenring 6

1010 Vienna

M: +43 676 848 191 462

[martin.busch@goeg.at](mailto:martin.busch@goeg.at)

[www.goeg.at](http://www.goeg.at)

